Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 4-(4-hydroxyphenyl)-1-naphthaldehyde oxime is a synthetic small molecule with the molecular formula C17H13NO2 and a molecular weight of approximately 263.29 g/mol[1][2][5]. It features both a naphthalene moiety and an oxime functional group, as well as a para-hydroxylated phenyl ring. This compound is primarily studied for its interaction with estrogen receptors, particularly estrogen receptor beta, where it acts as an inhibitor[5][7]. Its binding affinity and selectivity for estrogen receptor beta have been demonstrated in biochemical assays, suggesting potential utility in modulating diseases influenced by estrogen signaling[5]. However, it has not been approved for any clinical use and remains classified as experimental[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(4-hydroxyphenyl)-1-naphthaldehyde oxime.